Edwards Lifesciences 2005 Annual Report"
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular
design, offers optimal hemodynamics and flow characteristics for treatment
of aortic heart valve disease.
• Enables up to 23% greater effective orifice area (EOA).
• Designed on the foundation of the PERIMOUNT tissue (pericardial)
heart valve’s unparalleled 20-year durability.
• Now available with ThermaFix advanced tissue process – the
only tissue process that removes both major calcium binding sites.
No clinical data are available which evaluate the long-term impact of the Edwards tissue treatment in patients.
